AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 113096
Drug: Hexamethylmelamine at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexamethylmelamine at 6 mg/kg/day orally for 21 days every 4 weeks
Trial: 113096
Drug: Hexamethylmelamine at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexamethylmelamine at 8 mg/kg/day orally for 21 days every 6 weeks
Trial: 23669000
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of tranexamic acid
Trial: 20668790
Drug: Experimental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatment that enquires directly into childhood trauma and understands present interpersonal difficulties as a compulsion to repeat the traumatic past.
Trial: 20668790
Drug: Experimental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatment costs.
Trial: 20668790
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment costs.
Trial: 14640390
Drug: Prescription of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription of efavirenz to NNRTI-naive patients
Trial: 14640390
Drug: Prescription of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription of lamivudine
Trial: 14640390
Drug: Prescription of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription of abacavir to abacavir-naive patients
Trial: 14640390
Drug: Prescription of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription of nelfinavir
Trial: 10672626
Drug: Sibutramine 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine 25 mg
Trial: 10672626
Drug: Sibutramine 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine 75 mg
Trial: 10672626
Drug: d‐amphetamine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐amphetamine 20 mg
Trial: 1386491
Drug: Candoxatril (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candoxatril (150 mg twice daily)
Trial: 6654301
Drug: Etofenamate cream
RxNorm normalized name: etofenamate
DrugBank: Etofenamate (DB08984)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etofenamate cream
Trial: 6654301
Drug: Control medication
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Dial Dandruff Control]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control medication (salicylic acid ointment)
Trial: 20170881
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g vitamin C infusion (16.6 mg/min, over 1 h before percutaneous coronary intervention)
Trial: 20170881
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g vitamin C infusion
Trial: 19011435
Drug: Bupropion added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion added to nicotine replacement therapy (NRT) and cognitive behavioral therapy (CBT)
Trial: 19011435
Drug: Placebo added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo added to nicotine replacement therapy (NRT) and cognitive behavioral therapy (CBT)
Trial: 15708261
Drug: Cisplatin (C)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (C) - 40 mg/m² weekly for 6 doses concurrent with 50 Gy external beam radiotherapy
Trial: 15708261
Drug: Cisplatin plus
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin plus Gemcitabine (GC) - Gemcitabine 125 mg/m² plus Cisplatin 40 mg/m² weekly for 6 doses concurrent with 50 Gy external beam radiotherapy
Trial: 28526233
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human KGF (palifermin 60 μg/kg)
Trial: 23610448
Drug: Sunitinib (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (oral antiangiogenic tyrosine kinase inhibitor)
Trial: 23610448
Drug: Pazopanib (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib (oral antiangiogenic tyrosine kinase inhibitor)
Trial: 23610448
Drug: DC101 (antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DC101 (antibody targeting the VEGF pathway)
Trial: 17964811
Drug: Agent with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agent with open eyes
Trial: 17964811
Drug: Agent with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agent with sunglasses
Trial: 17964811
Drug: Agent with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agent with closed eyes
Trial: 17964811
Drug: Agent with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agent with occluders
Trial: 16537725
Drug: Fondaparinux 2.5
RxNorm normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fondaparinux 2.5 mg once daily for up to 8 days
Trial: 12750950
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium phosphate (NaP) in 2 doses (45 ml + 90 ml) plus domperidone
Trial: 12750950
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium phosphate (NaP) in one 90‐ml dose
Trial: 12750950
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium phosphate (NaP) in 2 doses (90 ml + 45 ml)
Trial: 12750950
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium phosphate (NaP) in 2 doses (45 ml + 90 ml) plus cisapride
Trial: 10977009
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g American ginseng (AG)
Trial: 10977009
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g (placebo)
Trial: 27342494
Drug: Lenalidomide +
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide + chemotherapy (LC)
Trial: 27342494
Drug: Chemotherapy +
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy + placebo (CP)
Trial: 22201336
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose etizolam for 2 weeks
Trial: 17142005
Drug: Intravenous propacetamol
RxNorm normalized name: 1,2,3-propanetriol, 2-(4-aminobenzoate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous propacetamol (P) 2 g every 6 hours
Trial: 17142005
Drug: Subcutaneous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous morphine (M) 0.05 mg/kg every 4 hours
Trial: 12142304
Drug: Relaxation and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation and flexibility (control treatment)
Trial: 10215768
Drug: ABL 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABL 0.1% in white soft paraffin applied twice daily for 2 weeks
Trial: 10215768
Drug: 1.0 microg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 microg/mL ABL
Trial: 10215768
Drug: 3.0 microg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 microg/mL ABL
Trial: 10215768
Drug: 30 microg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 microg/mL ABL
Trial: 10215768
Drug: 1.0 microg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 microg/mL ABL for 8 hours
Trial: 10215768
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of ABL 0.01% or 0.1%
Trial: 468096
Drug: Gastropulgit Tabs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastropulgit Tabs (2 tablets)
Trial: 468096
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (640 mg)
Trial: 26796709
Drug: Combined low‐level
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined low‐level laser therapy (LLLT) with passive stretching exercises
Trial: 22120829
Drug: ghrelin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ghrelin infusion 1 ng/kg/min
Trial: 22120829
Drug: ghrelin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ghrelin infusion
Trial: 17382029
Drug: Dual VEGF/EGFR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual VEGF/EGFR inhibition (e.g., erlotinib and bevacizumab, or vandetanib)
Trial: 2668787
Drug: Carbamazepine (CBZ)
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine (CBZ) 400 and 600 mg per day
Trial: 19390123
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy (blood glucose set at 80-110 mg/dL)
Trial: 19390123
Drug: Conventional insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional insulin therapy (blood glucose maintained at 180-200 mg/dL)
Trial: 12008861
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (impulse magnetic-field therapy)
Trial: 10493666
Drug: Prolactin (PRL)
RxNorm normalized name: prolactin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolactin (PRL) treatment of RA synovial cells
Trial: 10493666
Drug: Inhibitors of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibitors of PRL release (e.g., bromocriptine)
Trial: 8740792
Drug: Metoclopramide plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide plus dexamethasone plus lorazepam (M + D + L)
Trial: 1909241
Drug: Nimodipine 30
RxNorm normalized name: nimodipine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine 30 mg tds
Trial: 1909241
Drug: Nimodipine 60
RxNorm normalized name: nimodipine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine 60 mg tds
Trial: 1909241
Drug: Nimodipine 90
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nimodipine 90 mg tds
Trial: 6309637
Drug: Metoclopramide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (10 mg t.i.d.)
Trial: 30235049
Drug: TRT using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRT using 1%‐transdermal T‐gel (50 mg/day)
Trial: 18937999
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream applied once weekly for 24 weeks
Trial: 17456819
Drug: Ranolazine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranolazine (1000 mg twice daily, initiated intravenously)
Trial: 9737817
Drug: Diltiazem (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (60 mg four times daily for 21 doses)
Trial: 9737817
Drug: Diltiazem and
RxNorm normalized name: Diltiazem and enalapril only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem and Hydrochlorothiazide (combination)
Trial: 9737817
Drug: Hydrochlorothiazide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (25 mg twice daily for 11 doses)
Trial: 9737817
Drug: Hydrochlorothiazide and
RxNorm normalized name: hydrochlorothiazide and potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide and Diltiazem (combination)
Trial: 2729379
Drug: Regular coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular coffee (454 +/- 4 mg caffeine)
Trial: 2729379
Drug: Decaffeinated coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decaffeinated coffee (12 +/- 0.4 mg caffeine)
Trial: 28490712
Drug: Tofacitinib (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib (1 to 30 mg)
Trial: 28490712
Drug: Tofacitinib (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib (1 to 100 mg or 5 mg twice daily)
Trial: 23673101
Drug: Etoricoxib (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib (120 mg/d)
Trial: 23673101
Drug: Indometacin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indometacin (75 mg twice daily)
Trial: 19832873
Drug: Second injection
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second injection of glue
Trial: 19832873
Drug: Seton treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seton treatment after glue failure
Trial: 19716727
Drug: Cavit‐G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cavit‐G
Trial: 17477109
Drug: Blocking the
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Blocking the mineralocorticoid receptor with anti-aldosterone agents
Trial: 11159256
Drug: Carbamazepine (CMZ)
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine (CMZ) 600 mg/d
Trial: 11159256
Drug: Sustained-release morphine
RxNorm normalized name: morphine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release morphine 90 mg/d
Trial: 2516615
Drug: Sorbiphos (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorbiphos (2 g)
Trial: 2516615
Drug: Alu-Cap (950
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alu-Cap (950 mg)
Trial: 787738
Drug: Mersyndol (analgesic/antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mersyndol (analgesic/antihistamine combination containing paracetamol, codeine phosphate, doxylamine succinate, and caffeine)
Trial: 787738
Drug: Mersyndol (analgesic/antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mersyndol (analgesic/antihistamine combination)
Trial: 31803945
Drug: SBIRT +
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SBIRT + Alcohol Treatment
Trial: 31711088
Drug: Implants placed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implants placed in surgically bone-grafted sites
Trial: 31711088
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of adjacent implants
Trial: 28246207
Drug: FOLFIRI/simtuzumab 700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI/simtuzumab 700 mg
Trial: 28246207
Drug: FOLFIRI/simtuzumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI/simtuzumab 200 mg
Trial: 19856686
Drug: Fluid replacement
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid replacement therapy
Trial: 17053946
Drug: Extracorporeal shockwave
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shockwave treatment after open reduction and internal fixation
Trial: 17053946
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (open reduction and internal fixation without shockwave treatment)
Trial: 17053946
Drug: Extracorporeal shockwave
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shockwave treatment
Trial: 10916098
Drug: HCTZ (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCTZ (50 mg) + KHCO3 (60 mmol daily)
Trial: 10916098
Drug: HCTZ (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCTZ (50 mg) + KCl (60 mmol daily)
Trial: 10916098
Drug: KHCO3 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KHCO3 (60 mmol daily) alone
Trial: 9238885
Drug: Oral-B 20
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral-B 20 toothbrush
Trial: 30759696
Drug: Moderately hypofractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately hypofractionated radiation therapy (240-340 cGy per fraction)
Trial: 30759696
Drug: Ultrahypofractionated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrahypofractionated radiation therapy (500 cGy or more per fraction)
Trial: 30759696
Drug: Ultrahypofractionated external
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrahypofractionated external beam radiation therapy
Trial: 30759696
Drug: Image guided
RxNorm normalized name: triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Image guided radiation therapy
Trial: 15170704
Drug: Heparin only
RxNorm normalized name: Heparin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin only (Control)
Trial: 9638493
Drug: Electromyography and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electromyography and rectal sensitivity studies
Trial: 8088394
Drug: Allopurinol 200
RxNorm normalized name: allopurinol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol 200 mg orally at 24 h and 2 h preoperatively and again at 24 h postoperatively
Trial: 2683005
Drug: Alpha human
RxNorm normalized name: alpha 1-proteinase inhibitor, human Injection [Glassia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha human leukocyte interferon (IFN) ointment
Trial: 21678716
Drug: six-week treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: six-week treatment regimen for type 1 diabetes
Trial: 19284948
Drug: Changjishu soft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changjishu soft elastic capsule (4 capsules once daily, 3 times a day)
Trial: 16702330
Drug: Micronutrient-fortified seasoning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient-fortified seasoning powder (zinc 5 mg, iron 5 mg, vitamin A 270 microg, iodine 50 microg) served with school lunch 5 days/week for 31 weeks
Trial: 9093172
Drug: Standard preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard preparation of bisacodyl
Trial: 25499943
Drug: Mipomersen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mipomersen therapy
Trial: 23600790
Drug: Antacid (Milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid (Milk of Magnesia)
Trial: 10910606
Drug: HBV-NF vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV-NF vaccine
Trial: 7722114
Drug: Carvedilol (3.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (3.125 mg twice a day, titrated to 6.25 to 25 mg twice a day for < 75 kg or 50 mg twice a day for > 75 kg)
Trial: 2047947
Drug: Salbutamol 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol 1,000 micrograms by inhalation
Trial: 2047947
Drug: Salbutamol 200
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol 200 micrograms by inhalation
Trial: 22707179
Drug: Dignity therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dignity therapy (palliative care psychotherapy)
Trial: 22078241
Drug: mDOT (directly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mDOT (directly observed daily ribavirin plus provider-administered weekly IFN)
Trial: 22078241
Drug: TAU (self-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAU (self-administered ribavirin plus provider-administered weekly IFN)
Trial: 19735340
Drug: Routine information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine information preparation
Trial: 15157731
Drug: Earlier treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Earlier treatment of peripheral retina ablation
Trial: 6175933
Drug: Primary chemotherapy
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary chemotherapy (pc)
Trial: 6175933
Drug: Secondary chemotherapy
RxNorm normalized name: Secondary potassium phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secondary chemotherapy (sc)
Trial: 30859909
Drug: Concurrent Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent Control Group
Trial: 30227301
Drug: Glutathione 30
RxNorm normalized name: ASCORBIC ACID 250 mg in 7 g / .ALPHA.-TOCOPHEROL 20 mg in 7 g / THIAMINE 1 mg in 7 g / MARINE COLLAGEN, SOLUBLE 500 mg in 7 g / PEARL (HYRIOPSIS CUMINGII) 500 mg in 7 g / GLUTATHIONE 300 mg in 7 g / PHLEBODIUM AUREUM LEAF 120 mg in 7 g / PHLEBODIUM AUREUM ROOT 120 mg in 7 g / HYALURONIC ACID 50 mg in 7 g / LYCOPENE 1.15 mg in 7 g / ALOE VERA LEAF 50 mg in 7 g / OPHIOCORDYCEPS SINENSIS 100 mg in 7 g / SOYBEAN 100 mg in 7 g / RICE BRAN 100 mg in 7 g / MARITIME PINE 60 mg in 7 g / HONEY 100 mg in 7 g ORAL POWDER [JBA Collagen-A]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutathione 30 mg L-1
Trial: 30227301
Drug: Glutathione 50
RxNorm normalized name: glutathione 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutathione 50 mg L-1